Researchers reported long-term exploratory analyses of subgroups defined by response to first-line chemotherapy in the phase 3 JAVELIN Bladder 100 trial.
Results were presented at the American Urology Association 2023 Annual Meeting.
JAVELIN Bladder 100 showed first-line avelumab maintenance plus best supportive care (BSC) significantly prolonged overall survival (OS) compared with BSC alone in patients with advanced urothelial carcinoma who had not progressed on first-line platinum-based chemotherapy.
Begoña Valderrama, MD, and colleagues conducted exploratory analyses based on response to first-line chemotherapy (complete response [CR], partial response [PR], or stable disease [SD]) after at least 2 years of follow-up, as well as visceral versus nonvisceral disease at chemotherapy initiation.
At data cutoff, median follow-up in both treatment arms (avelumab plus BSC or BSC alone) was ≥38 months. Researchers reported prolonged OS and progression-free survival in the avelumab-plus-BSC arm in all subgroups.
Additionally, they noted that subsequent second-line anticancer drug therapy was received in all subgroups (CR subgroup, 50.0% vs 74.2%, respectively; PR subgroup, 58.3% vs 71.8%; SD subgroup, 46.4% vs 70.4%).
Long-term safety was consistent across subgroups, they added.
“These findings further support avelumab first-line maintenance as standard of care for all patients with advanced urothelial carcinoma who have not progressed with first-line platinum-based chemotherapy,” Dr. Valderrama and colleagues concluded.
